Johnson & Johnson’s COVID-19 vaccine could find yourself being a two-dose routine if it proves to supply extra safety than one, a White House adviser mentioned Thursday.
“Johnson & Johnson is at the moment evaluating how their vaccine performs with two doses — in different phrases, their very own booster,” Andy Slavitt, a senior adviser to the COVID-19 response staff, mentioned in an interview on Washington Publish Stay.
“Pending the outcomes of that, pending what the FDA has to say if the vaccine is authorised within the first place, there might be a second shot of Johnson & Johnson.”
The drugmaker introduced a large-scale trial to check the two-dose routine in November.
The corporate mentioned it deliberate to enroll as many as 60,000 members worldwide for the research, which was run parallel with a one-dose trial.
The members are given both a placebo or the experimental shot, at the moment referred to as Advert26COV2, adopted by a second dose or placebo 57 days later.
“The research will assess efficacy of the investigational vaccine after each the primary and second dose to judge safety in opposition to the virus and potential incremental advantages for length of safety with a second dose,” J&J mentioned in a press release.
The corporate has already filed for emergency authorization of its one-dose COVID-19 vaccine, which has proven to be 66 p.c efficient in opposition to average to extreme instances.
Whether it is authorised by the Meals and Drug Administration, it should go head-to-head with two-dose rivals Pfizer and Moderna, each of which supply greater than 90 p.c efficacy.
With Publish wires